[go: up one dir, main page]

BR112014014960A2 - métodos para o diagnóstico da doença de alzheimer - Google Patents

métodos para o diagnóstico da doença de alzheimer

Info

Publication number
BR112014014960A2
BR112014014960A2 BR112014014960A BR112014014960A BR112014014960A2 BR 112014014960 A2 BR112014014960 A2 BR 112014014960A2 BR 112014014960 A BR112014014960 A BR 112014014960A BR 112014014960 A BR112014014960 A BR 112014014960A BR 112014014960 A2 BR112014014960 A2 BR 112014014960A2
Authority
BR
Brazil
Prior art keywords
methods
disease
abstract
diagnosing
amyloidosis
Prior art date
Application number
BR112014014960A
Other languages
English (en)
Inventor
Holtzman David
Bateman Randall
Original Assignee
Univ Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Washington filed Critical Univ Washington
Publication of BR112014014960A2 publication Critical patent/BR112014014960A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

abstract: front page image (en)the present invention relates to methods of diagnosing, monitoring, and assessing treatment effects for aß amyloidosis, early in the course of clinical disease or prior to the onset of brain damage and clinical symptoms. methods of measuring the in vivo metabolism of biomolecules produced in the cns in a subject are provided. tradução do resumo resumo patente de invenção: "métodos para o diagnóstico da doença de alzheimer". a presente invenção refere-se aos métodos de diagnóstico, mo-nitoramento e avaliação dos efeitos de tratamento para a aß amiloidose, no início do curso da doença clínica ou antes do começo das lesões cerebrais e sintomas clínicos. os métodos de medição do metabolismo in vivo das bio-moléculas produzidas no cns em um indivíduo são fornecidos.
BR112014014960A 2011-12-19 2012-12-19 métodos para o diagnóstico da doença de alzheimer BR112014014960A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577439P 2011-12-19 2011-12-19
PCT/US2012/070623 WO2013096451A2 (en) 2011-12-19 2012-12-19 Methods for diagnosing alzheimer's disease

Publications (1)

Publication Number Publication Date
BR112014014960A2 true BR112014014960A2 (pt) 2017-06-13

Family

ID=48669694

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014014960A BR112014014960A2 (pt) 2011-12-19 2012-12-19 métodos para o diagnóstico da doença de alzheimer

Country Status (8)

Country Link
US (2) US20140370619A1 (pt)
EP (1) EP2795325B9 (pt)
JP (1) JP6129868B2 (pt)
AU (1) AU2012359020B2 (pt)
BR (1) BR112014014960A2 (pt)
CA (1) CA2859808A1 (pt)
WO (1) WO2013096451A2 (pt)
ZA (1) ZA201404500B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2861600T3 (es) 2014-04-04 2021-10-06 Mayo Found Medical Education & Res Isotipaje de inmunoglobulinas usando masa molecular precisa
US11231413B2 (en) 2014-05-22 2022-01-25 Shimadzu Corporation Surrogate biomarker for evaluating intracerebral amyloid ß peptide accumulation and method for analysis thereof
WO2016018978A1 (en) 2014-07-29 2016-02-04 Mayo Foundation For Medical Education And Research Quantifying monoclonal antibody therapeutics by lc-ms/ms
WO2016054247A1 (en) 2014-09-30 2016-04-07 Washington University Tau kinetic measurements
EP4424704A3 (en) * 2015-09-16 2024-12-25 Shimadzu Corporation Multiplex biomarker for use in evaluation of state of accumulation of amyloid b in brain, and analysis method for said evaluation
EP3353200A4 (en) 2015-09-24 2019-06-26 Mayo Foundation for Medical Education and Research IDENTIFICATION OF FREE LIGHT CHAINS FROM IMMOBILIZED LOBULIN BY MASS SPECTROMETRY
US11360098B2 (en) * 2015-09-28 2022-06-14 Quest Diagnostics Investments Llc Amyloid beta detection by mass spectrometry
EP3523647B1 (en) 2016-09-07 2024-06-26 Mayo Foundation for Medical Education and Research Identification and monitoring of cleaved immunoglobulins by molecular mass
JP7236737B2 (ja) 2016-10-28 2023-03-10 ワシントン・ユニバーシティ 抗ａｐｏｅ抗体
US12066444B2 (en) 2017-05-01 2024-08-20 Washington University Blood-based methods for determining Aβ amyloidosis
EP3681907A4 (en) 2017-09-13 2021-07-07 Mayo Foundation for Medical Education and Research IDENTIFICATION AND MONITORING OF IMMUNOGLOBULIN CHAINS J
US11085935B2 (en) 2018-05-03 2021-08-10 Washington University Methods of treating based on site-specific tau phosphorylation
US12145988B2 (en) 2018-09-11 2024-11-19 Washington University Anti-TREM-2 agonist antibodies

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60324393D1 (de) * 2002-02-12 2008-12-11 Univ California Nichtinvasive messung der biosynthese- und abbaugeschwindigkeiten biologischer moleküle, die einer direkten probenahme unzugänglich oder nicht leicht zugänglich sind, durch einbau einer markierung in metabolische derivate und katabole produkte
CA2604057C (en) * 2005-04-06 2014-02-11 Randall John Bateman Methods for measuring the metabolism of neurally derived biomolecules in vivo
US20110143380A1 (en) * 2006-03-14 2011-06-16 The Washington University Alzheimer's disease biomarkers and methods of use
BRPI0714930A2 (pt) * 2006-07-28 2013-05-21 Adlyfe Inc sondas peptÍdicas para fins diagnàsticos e terapÊuticos
WO2009062152A1 (en) * 2007-11-09 2009-05-14 Washington University In St. Louis Methods for measuring the metabolism of cns derived biomolecules in vivo
CN102666577A (zh) * 2009-11-24 2012-09-12 前体生物药物股份公司 诊断阿尔茨海默病或轻度认知损害的新的诊断方法
ES2583033T3 (es) * 2010-05-24 2016-09-16 The Washington University Métodos de determinación del recambio de amiloide beta en sangre

Also Published As

Publication number Publication date
AU2012359020B2 (en) 2017-04-13
EP2795325A2 (en) 2014-10-29
WO2013096451A3 (en) 2014-09-25
US20140370619A1 (en) 2014-12-18
ZA201404500B (en) 2017-09-27
US20160169916A1 (en) 2016-06-16
AU2012359020A1 (en) 2014-07-10
EP2795325A4 (en) 2016-02-17
JP2015505365A (ja) 2015-02-19
EP2795325B1 (en) 2017-09-13
WO2013096451A2 (en) 2013-06-27
CA2859808A1 (en) 2013-06-27
JP6129868B2 (ja) 2017-05-17
EP2795325B9 (en) 2017-11-15

Similar Documents

Publication Publication Date Title
BR112014014960A2 (pt) métodos para o diagnóstico da doença de alzheimer
Schmid et al. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies
Vlassenko et al. PET amyloid-beta imaging in preclinical Alzheimer's disease
HUE036177T2 (hu) TAU-mediált patológia protein alapú terápiája és diagnózisa Alzheimer-betegségben
IL225930B (en) Apparatus and method for detecting amyloid in a retina in a diagnosis, advancement, and prognosing of alzheimer's disease, traumatic brain injury, macular degeneration and a plurality of neurodegenerative dissorders, and ocular diseases
EP2877605A4 (en) SCREENING, DIAGNOSIS AND PROGNOSIS OF AUTISM AND OTHER DEVELOPMENT DISORDERS
ECSP13012609A (es) Composición farmacéutica
MX349711B (es) Método óptico para la detección de la enfermedad de alzheimer.
WO2013128293A3 (en) Methods, apparatuses and systems for diagnosis and treatment of mood disorders
BR112013017745A2 (pt) métodos para o diagnóstico e tratamento de distúrbios relacionados ao comprimento do olho
EP2529033A4 (en) METHOD AND COMPOSITIONS FOR RISK OVERVIEW, DIAGNOSIS, FORECASTING AND TREATMENT OF LUNG DISEASES
IN2014DN08398A (pt)
MX375108B (es) Compuestos y composiciones para la deteccion y el tratamiento de la enfermedad de alzheimer y trastornos relacionados.
WO2015014903A3 (en) Diagnostic tools for alzheimer's disease
MX2013015409A (es) Diagnostico de la enfermedad de alzheimer.
WO2013060788A3 (en) Method and use of metabolites for the diagnosis and differentiation of neonatal encephalopathy
CO6450654A2 (es) Identificación de moléculas pequeñas reconocidas por anticuerpos en sujetos con enfermedades neurodegenerativas
BR112012026224A2 (pt) métodos para tratar mal de alzheimer e para avaliar a eficácia de uma terapia
BR112014009223A2 (pt) método para o diagnóstico da doença de niemann-pick
Martinez-Martin et al. Measurement of nonmotor symptoms in clinical practice
BR112015014232A2 (pt) lesão renal aguda
BR112013031431A2 (pt) método para o diagnóstico da doença de gaucher
EP2895856A4 (en) DIAGNOSIS AND TREATMENT OF DISTURBANCES OF THE DARM AND BUBBLE AND FIBROMYALGIA
WO2015069883A3 (en) Oxidized fraction of extracellular dna as a biomarker of stress and methods for using the same
BR112017027304A2 (pt) método para o diagnóstico de doença de farber

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]